Results 21 to 30 of about 3,395 (155)

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]

, 2017
BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P, Hingorani, Aroon D, Overington, John P, Pearce, Lucy S, Schmidt, Amand F, Wilkins, John T   +5 more
core   +2 more sources

Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

Biomedicines, 2022
Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich ...
Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel   +11 more
doaj   +1 more source

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk:Rationale and design of the ODYSSEY DM-INSULIN trial [PDF]

, 2017
Aims: The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study.
A. Letierce, Arsenault, B. Cariou, Brouwers, Cannon, Cannon, Cariou, Cariou, Catapano, Chillaron, Colhoun, Colhoun, Crosby, D. Müller-Wieland, de Ferranti, F.J. Tinahones, Feingold, G. Bigot, Ginsberg, H.M. Colhoun, J. Maroni, Jacobson, K.K. Ray, Kearney, Kereiakes, Koren, L. Aurand, L.A. Leiter, Langhi, Lee, Leiter, Lind, M. Bujas-Bobanovic, Mooradian, Piepoli, Preiss, R.R. Henry, Robinson, Roth, Ryden, S. Del Prato, Sattar, Schwartz, Sever, Tatlock, Toth, Turner, Verges, Wong, Wong   +49 more
core   +1 more source

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab [PDF]

Kosin Medical Journal
Background The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and
Su-Hyun Bae, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo   +5 more
doaj   +1 more source

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Frontiers in Pharmacology, 2021
Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain.
Zhe Liang, Qi Chen, Ruiqi Wei, Chenyao Ma, Xuehui Zhang, Xue Chen, Fang Fang, Quanming Zhao   +7 more
doaj   +1 more source

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
Background The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol (LDL‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 
Erik Stroes, John R. Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F. Watts, Marie T. Baccara‐Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier, the ODYSSEY CHOICE II Investigators   +10 more
doaj   +1 more source

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Cardiovascular Diabetology, 2019
Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and ...
Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter   +11 more
doaj   +1 more source

The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update [PDF]

, 2016
The clinical indications and guidelines for low-density lipoprotein (LDL)-apheresis set by the 1(st) Italian Consensus Conference held in Ostuni in 1990 and completed in 1992, but never published, are reported schematically.
Stefanutti, Claudia
core   +1 more source

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

Frontiers in Cardiovascular Medicine, 2022
BackgroundProprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been documented with significantly reduction in LDL cholesterol levels and cardiovascular events.
Fei Gao, Yue Ping Li, Xiao Teng Ma, Zhi Jian Wang, Dong Mei Shi, Yu Jie Zhou   +5 more
doaj   +1 more source

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials

Cardiology Journal, 2022
BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab
Qiang Geng, Xuan Li, Qingjiao Sun, Zhengzhong Wang   +3 more
doaj   +1 more source